Next Significant Milestone, page-30

Dude, biotech. It takes time (not that I am at all excusing OCC management's tardiness in many areas).

By your own admission you sold out of a huge parcel of OCC, that has FDA, EMA and TGA approvals already, to buy into another biotech that can at best be described as a phase I/II trial stage cancer immunotherapies biotech company, with no approvals, in a hotly contested market saturated by dozens of CAR T-cell and NK cell researching companies globally.

If you are bothered by the wait in OCC, which is further along and has far less arduous pathways, I fear you will be even more frustrated by your investment in the other company and its likely timeline to commercial success.